---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023254"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:03:58.971214+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q3 net loss $14.8M; pauses ENLIGHTEN II enrollment for in-house mfg

## Summary
- Net loss of $14.8M for Q3 2022, compared to $11.1M in Q3 2021.
- Cash and equivalents $109.6M; expected to fund operations through mid-2024.
- ENLIGHTEN I Phase 3 trial on track for enrollment completion mid-2023; ENLIGHTEN II paused, resuming Q3 2023.
- BEACON Phase 2 trial of LYR-220 advanced to randomized stage; initial data submitted for 2023 meeting.
- R&D expenses rose to $10.0M from $7.1M year-over-year due to clinical trial costs.

## SEC filing metadata
- accession: 0000950170-22-023254
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/0000950170-22-023254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/lyra-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023254
- JSON: https://secwatch.observer/filing/0000950170-22-023254.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023254.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $14.8 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss for the quarter ended September 30, 2022 was $14.8 million
  - Result: reported results
  source text: On November 8, 2022, Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017022023254/0000950170-22-023254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.